Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $51.22.

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a report on Monday, August 5th. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research note on Thursday, October 17th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Finally, Barclays reduced their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 5th.

Twist Bioscience Stock Performance

TWST traded up $0.36 during trading on Friday, hitting $40.60. The stock had a trading volume of 593,422 shares, compared to its average volume of 955,359. The stock has a 50 day simple moving average of $43.83 and a two-hundred day simple moving average of $44.63. Twist Bioscience has a twelve month low of $14.42 and a twelve month high of $60.90. The company has a market capitalization of $2.36 billion, a PE ratio of -12.08 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analysts' expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business's revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.01) earnings per share. On average, equities research analysts anticipate that Twist Bioscience will post -3.13 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 13,605 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $587,872.05. Following the sale, the chief executive officer now owns 481,918 shares in the company, valued at approximately $20,823,676.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Patrick John Finn sold 2,885 shares of the business's stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $115,198.05. Following the completion of the sale, the chief operating officer now directly owns 168,327 shares in the company, valued at $6,721,297.11. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 13,605 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $587,872.05. Following the transaction, the chief executive officer now owns 481,918 shares in the company, valued at $20,823,676.78. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,300 shares of company stock worth $1,801,822. Corporate insiders own 3.92% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the 2nd quarter worth about $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after acquiring an additional 381 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.